Eris Lifesciences Investor Presentation - Q2 FY26
Eris Lifesciences releases its investor presentation for Q2 FY26, reporting revenue and EBIDTA growth. Key highlights include expansion of insulin capacity and strategic partnerships.
The information suggests a positive outlook due to revenue and EBIDTA growth, capacity expansion, and strategic partnerships. However, the impact is medium as it reflects ongoing performance and planned activities rather than immediate, transformative changes.
The announcement highlights positive financial performance, strategic expansions, and partnerships, indicating a positive outlook for the company.
* Eris Lifesciences Limited has released its investor presentation for Q2 FY26 on 12 November 2025. * DBF Revenue performance: Q2 growth of 10% yoy and H1 growth of 11% yoy. * DBF EBIDTA performance: Growth of 11% yoy in Q2 and 13% yoy in H1. Margin expansion by 32 bps yoy to 37.6% in Q2 and by 93 bps yoy to 37.3% in H1. * Eris is adding Aspart to the scope of the strategic collaboration between Eris and Biocon. * Eris Bionxt is expanding to double insulin capacity with a Capex of ₹150 crore (₹1,500 million), expecting an EBIDTA potential of at least ₹50 crore (₹500 million) p.a. from the additional market opportunity. * Eris' AMD unit received ANVISA approval for the oral liquids line; targeting ANVISA inspection of oral solids and injectables line in Jan-26. * Capex outlay of ₹380-400 crore (₹3,800-4,000 million) over the next 3 quarters will be funded through internal accruals. * Q2 Revenue = ₹792 crore (₹7,920 million) - up 7% yoy (9% ex. Trade Gx). * Q2 EBIDTA = ₹288 crore (₹2,880 million) - up 9% yoy (11% ex. Trade Gx). * Q2 PAT = ₹134 crore (₹1,340 million) - up 39% yoy. * H1 Revenue = ₹1,565 crore (₹15,650 million) - up 7% yoy (9% ex. Trade Gx). * H1 EBIDTA = ₹565 crore (₹5,650 million) - up 10% yoy (12% ex. Trade Gx). * H1 PAT ~ ₹260 crore (₹2,600 million) - up 40% yoy.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.